FDA approves Axogen's BLA for AVANCE® (acellular nerve allograft-arwx). Dec. 03, 2025: Axogen, Inc. announces FDA approval.

Unusual Whales
2025.12.04 01:03
In Alachua, Florida and Tampa, Florida on December 3, 2025, Axogen, Inc. (NASDAQ: AXGN), a prominent company in the advancement and promotion of cutting-edge surgical technologies for revitalizing peripheral nerve function, revealed that the U.S. Food and Drug Administration (FDA) has given the green light to the Biologics License Application (BLA) for AVANCE® (acellular nerve allograft-arwx).
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer